Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(bezlotoxumab)
94 results
  • Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection. [Journal Article]
    Clin Infect Dis 2019Kelly CP, Poxton IR, … Dorr MB
  • CONCLUSIONS: Higher eAb titers against toxin B, but not toxin A, were associated with protection against rCDI. These data are consistent with the observed efficacy of bezlotoxumab, and lack of efficacy of actoxumab, in the MODIFY trials.High titers of endogenous antibodies to Clostridioides difficile toxin B, but not toxin A, were associated with reduced recurrence of C. difficile infection. These findings are consistent with efficacy data from the phase 3 MODIFY trials of bezlotoxumab and actoxumab.
  • Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI. [Review]
    Rev Esp Quimioter 2019; 32 Suppl 2:47-54Castro I, Tasias M, … Salavert M
  • Recurrence rate ranges from 12% to 40% of all cases of Clostridium difficile infection (CDI) and proposes an exceptional clinical challenge. Conventionally, treatment options of CDI have been limited to regimes of established antibiotics (eg, pulsed/tapered vancomycin) or "improvised" alternative antibiotics (eg. teicoplanin, tigecycline, nitazoxanide or rifaximin) occasionally even in combinatio…
  • Assessment of Bezlotoxumab Immunogenicity. [Journal Article]
    Clin Pharmacol Drug Dev 2019Montgomery DL, Matthews RP, … Wrishko RE
  • Bezlotoxumab is a fully human monoclonal antibody that binds and neutralizes Clostridium difficile toxin B. This analysis investigated the potential of bezlotoxumab to induce immunogenicity in healthy phase 1 trial participants and in phase 2/3 trial participants receiving oral antibacterial therapy for primary or recurrent C difficile infection. Immunogenicity to bezlotoxumab was evaluated follo…
New Search Next